Broadly neutralizing aptamers to SARS-CoV-2: A diverse panel of modified DNA antiviral agents
Authors:
Open Access
- 20 January 2023
- journal article
- research article
- Published by Elsevier in Molecular Therapy Nucleic Acids
- Vol. 31, 370-382
Abstract
No abstract availableKeywords
This publication has 40 references indexed in Scilit:
- Andromeda: A Peptide Search Engine Integrated into the MaxQuant EnvironmentJournal of Proteome Research, 2011
- Aptamer-Based Multiplexed Proteomic Technology for Biomarker DiscoveryPLOS ONE, 2010
- Expanding the Chemistry of DNA for in Vitro SelectionJournal of the American Chemical Society, 2010
- Activation of the SARS coronavirus spike protein via sequential proteolytic cleavage at two distinct sitesProceedings of the National Academy of Sciences of the United States of America, 2009
- MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantificationNature Biotechnology, 2008
- An Aptamer That Neutralizes R5 Strains of Human Immunodeficiency Virus Type 1 Blocks gp120-CCR5 InteractionJournal of Virology, 2005
- Structural characterization of an anti-gp120 RNA aptamer that neutralizes R5 strains of HIV-1RNA, 2005
- Neutralization of Infectivity of Diverse R5 Clinical Isolates of Human Immunodeficiency Virus Type 1 by gp120-Binding 2′F-RNA AptamersJournal of Virology, 2003
- The Coronavirus Spike Protein Is a Class I Virus Fusion Protein: Structural and Functional Characterization of the Fusion Core ComplexJournal of Virology, 2003
- Systematic Evolution of Ligands by Exponential Enrichment: RNA Ligands to Bacteriophage T4 DNA PolymeraseScience, 1990